Good evening :)
Place Order
Add to Watchlist

Abbott India Ltd

ABBOTINDIA

Abbott India Ltd

ABBOTINDIA
Health CarePharmaceuticals
MidcapWith a market cap of ₹61,304 cr, stock is ranked 156
Low RiskStock is 1.65x as volatile as Nifty
29,035.250.02% (-4.75)
29,035.250.02% (-4.75)

Price Chart

High
—
Low
—
Returns
—
1D
1W
1M
1Y
5Y
Max
SIP
Loading...
1D
1W
1M
1Y
5Y
Max
SIP
Health CarePharmaceuticals
MidcapWith a market cap of ₹61,304 cr, stock is ranked 156
Low RiskStock is 1.65x as volatile as Nifty
Scorecard

Performance

Low

Hasn't fared well - amongst the low performers

Valuation

High

Seems to be overvalued vs the market average

Growth

Low

Lagging behind the market in financials growth

Profitability

High

Showing good signs of profitability & efficiency

Entry point

Avg

The stock is overpriced but is not in the overbought zone

Red flags

Low

No red flag found

How to use scorecard? Learn more

Health CarePharmaceuticals
MidcapWith a market cap of ₹61,304 cr, stock is ranked 156
Low RiskStock is 1.65x as volatile as Nifty

Key Metrics

No LabelNo LabelPB RatioPB RatioDividend YieldDiv. Yield
47.7216.571.42%
Sector PESector PESector PBSector PBSector Div YldSctr Div Yld
51.906.610.52%

Forecast & Ratings

Detailed Forecast 
83%
Analysts have suggested that investors can buy this stock

from 6 analysts

Price

Price Upside

Earnings

Earnings Growth

Revenue

Rev. Growth

See Detailed Forecast

Company Profile

Abbott India is a healthcare company engaged in pharmaceuticals business. The Company has a portfolio of offerings in diagnostics, medical devices, nutritionals and branded generic pharmaceuticals.

Get more out of Tickertape, Go Pro!

Customise key metrics, see detailed forecasts, download stock data and more

Forecasts

Price

Revenue

Earnings

Income

Balance Sheet

Cash Flow

Income Statement

Industry refers to the sub-sector this company belongs to.

Higher than Industry Revenue Growth

A higher-than-industry revenue growth represents increased potential for the company to increase their market share

Over the last 5 years, revenue has grown at a yearly rate of 10.06%, vs industry avg of 9.03%

Decreasing Market Share

Market share is the percentage of an industry's total sales going to a particular company. It gives a general idea of the size of a company v/s its competitors

Over the last 5 years, market share decreased from 1.73% to 1.62%

Higher than Industry Net Income

Net income is equal to net earnings (profit) less expenses. This number is an important measure of how profitable the company is

Over the last 5 years, net income has grown at a yearly rate of 21.68%, vs industry avg of 15.27%

Loading...

Financial YearFY 2016FY 2017FY 2018FY 2019FY 2020FY 2021FY 2022FY 2023FY 2024TTM
Total Revenue2,665.092,960.203,415.493,791.894,207.534,390.925,015.735,533.236,123.536,330.62
Raw Materialssubtract1,477.161,813.512,006.942,090.782,254.392,494.922,679.492,908.973,212.884,518.86
Power & Fuel Costsubtract6.987.7410.2612.6113.7312.7414.9817.1516.63
Employee Costsubtract341.09345.27393.69435.58476.11492.65579.46563.59576.58
Selling & Administrative Expensessubtract343.35353.66365.41432.83400.27366.98459.18467.74429.89
Operating & Other expensessubtract81.54-14.93-2.30102.07192.1921.27117.69216.00186.18
Depreciation/Amortizationsubtract14.4416.4316.1916.9259.6158.1366.1069.9771.1772.04
Interest & Other Itemssubtract2.522.043.822.258.5318.2819.1015.9912.4511.23
Taxes & Other Itemssubtract142.76159.84220.26248.52209.77235.26281.03324.41416.53443.83
EPS120.12130.19188.82211.93279.04325.04375.87446.80565.30604.57
DPS35.0040.0055.0065.00250.00275.00275.00325.00410.00410.00
Payout ratio0.290.310.290.310.900.850.730.730.730.68

Company Updates

Annual Report and Investor Presentation updates mentioned here are as reported by the company to the exchange

Peers & Comparison

Comparing 3 stocks from 
Health CarePharmaceuticals

Loading...

StockPE RatioPE RatioPB RatioPB RatioDiv. YieldDividend Yield
Abbott India Ltd51.0316.571.42%
Sun Pharmaceutical Industries Ltd45.106.440.75%
Cipla Ltd29.414.520.87%
Torrent Pharmaceuticals Ltd68.5016.550.84%

Price Comparison

Compare ABBOTINDIA with any stock or ETF
Compare ABBOTINDIA with any stock or ETF
ABBOTINDIA
Loading...

Shareholdings

Promoter Holdings Trend

Total Promoter Holding

Increasing promoter holding is considered good and reflects management’s positive view about the future outlook

In last 6 months, promoter holding in the company has almost stayed constant

Low Pledged Promoter Holding

Lower pledged promoter holdings is considered better

Pledged promoter holdings is insignificant

Institutional Holdings Trend

Total Retail Holding

Increasing retail holding can be considered bad as it can reflect that institutions and promoters are selling their stake which is being absorbed by retail investors.

In last 3 months, retail holding in the company has almost stayed constant

Foreign Institutional Holding

Foreign Institutional Holding is quantum of stock held by foreign large-quantities-trading entities. Increasing value indicates growing support and comfort for the stock

In last 3 months, foreign institutional holding of the company has almost stayed constant

Tickertape Separator

Shareholding Pattern

Retail and OthersForeign InstitutionsOther Domestic InstitutionsMutual FundsTotal Promoter Holding74.99%7.69%1.31%0.16%15.86%

Dec 2023

Mar 2024

Jun 2024

Sep 2024

Shareholding History

JunSepDec '23MarJunSep0.19%0.18%0.18%0.18%0.18%0.16%

Mutual Funds Holding Trend

Mutual Fund Holding

Increasing Mutual Fund holdings are generally considered good, as it reflects that fund managers are becoming more bullish about the stock

In last 3 months, mutual fund holding of the company has almost stayed constant

Top 5 Mutual Funds holding Abbott India Ltd




Funds (Top 5)Market-cap heldWeight3M holding changePortfolio rank
(3M change)
SBI Large & Midcap Fund - Growth - Direct Plan

Growth
1.2994%2.78%0.24%45/86 (0)
Axis Midcap Fund - Growth - Direct Plan

Growth
0.7763%1.59%0.08%21/113 (0)
Canara Robeco Emerging Equities - Growth - Direct Plan

Growth
0.7278%1.85%0.01%12/96 (+1)

Compare 3-month MF holding change on Screener

Insider Trades & Bulk Deals

Hmm, looks like there hasn't been any net deal activity in the last 6 months

smallcases

Looks like this stock is not in any smallcase yet.

Events

Dividend Trend

No Dividend Cuts

Dividends are the portion of earnings that a company distributes to all its shareholders every year

ABBOTINDIA has increased or maintained dividend levels over the last 5 years

Dividend Yield

Dividend return is one of the most important things to be considered while investing for long term. It is the additional return on top of what investors earn through price appreciation

Current dividend yield is 1.42%. An investment of ₹1,000 in the stock is expected to generate dividend of ₹14.21 every year

Dividends

Corp. Actions

Announcements

Legal Orders

Upcoming Dividends

No upcoming dividends are available

Past Dividends

Cash Dividend

Ex DateEx DateJul 19, 2024

Final
Final | Div/Share: ₹410.00

Dividend/Share

₹410.00

Ex DateEx Date

Jul 19, 2024

Cash Dividend

Ex DateEx DateJul 21, 2023

Special
Special | Div/Share: ₹145.00

Dividend/Share

₹145.00

Ex DateEx Date

Jul 21, 2023

Cash Dividend

Ex DateEx DateJul 21, 2023

Final
Final | Div/Share: ₹180.00

Dividend/Share

₹180.00

Ex DateEx Date

Jul 21, 2023

Cash Dividend

Ex DateEx DateAug 2, 2022

Final
Final | Div/Share: ₹145.00

Dividend/Share

₹145.00

Ex DateEx Date

Aug 2, 2022

Cash Dividend

Ex DateEx DateAug 2, 2022

Special
Special | Div/Share: ₹130.00

Dividend/Share

₹130.00

Ex DateEx Date

Aug 2, 2022

News & Opinions
Spotlight
Abbott launches new pneumococcal vaccine for kids

According to the regulatory filing, the new vaccine provides broader protection against pneumococcal disease, covering 14 different serotypes (strains) of the bacteria, making it more comprehensive than the existing PCV-10 and PCV-13 vaccines. A conjugate vaccine is a distinct type of vaccine that combines a part of the bacteria with a protein to make it work better. This helps the immune system recognize and fight off the bacteria more effectively, making it stronger against certain infections, which can result in severe diseases, especially among children. Children under five years of age, especially those aged two years or under, face a high risk of pneumococcal disease, which is caused by a bacterial infection.i Pneumococcal infections can result in a range of conditions, including pneumonia, meningitis (inflammation of the tissues surrounding the brain and spinal cord), or blood infections, collectively known as Invasive Pneumococcal Disease (IPD). Vaccination can protect against some of these infections and can prevent complications in children. IPD is associated with high mortality in children under five years of age, resulting in 14% of deaths in India. The PCV-14 vaccine protects against five more strains than the PCV 10, and two more strains than the PCV 13 vaccines that are currently used in India, in private clinics and hospitals. The recommended immunization schedule for PneumoShield 14, which is administered via intramuscular injections, is at 6, 10, and 14 weeks. Swati Dalal, managing director, Abbott India, commented, 'Children, especially those under two years old, are at a higher risk of having pneumococcal disease. This can hinder their healthy growth and development and increase the risk of complications. This innovation offers broader protection potential against 14 pneumococcal strains in circulation, which cause the majority of pneumococcal-related diseases in India. Introducing this vaccine is another step in our commitment to further strengthen our pediatric portfolio, to help children stay healthy.' Vijay Yewale, Pediatrician, Yewale Hospital, Mumbai added, 'Immunization offers an important protective solution for parents to fight off pneumococcal-related diseases such as pneumonia and meningitis, especially among children. Considering the challenges in diagnosing and treating such diseases, there is a clear need for advanced vaccines with a wider representation of relevant pneumococcal bacteria strains. This in turn, helps provide broader protection against pneumococcal disease amongst children.' Abbott India has a portfolio of science-based offerings in diagnostics, medical devices, nutritionals and branded generic pharmaceuticals. The company's standalone net profit increased 14.6% to Rs 358.61 crore in Q2 FY25 as compared with Rs 312.94 crore in Q2 FY24. Revenue from operations was at Rs 1,632.67 crore in Q2 FY25, up 9.3% from Rs 1,632.67 crore reported in the same quarter previous year. The scrip shed 0.56% to Rs 27,350 on the BSE. Powered by Capital Market - Live

1 week agoCapital Market - Live
Corporate
Board of Abbott India appoints director

The Board of Abbott India at its meeting held on 07 November 2024 has approved the appointment of Sridhar Kadangode (DIN: 06715478) as an Additional Director of the Company with effect from 07 November 2024. Powered by Capital Market - Live

4 weeks agoCapital Market - Live
Earnings
Abbott India standalone net profit rises 14.59% in the September 2024 quarter

Net profit of Abbott India rose 14.59% to Rs 358.61 crore in the quarter ended September 2024 as against Rs 312.94 crore during the previous quarter ended September 2023. Sales rose 9.27% to Rs 1632.67 crore in the quarter ended September 2024 as against Rs 1494.14 crore during the previous quarter ended September 2023. ParticularsQuarter EndedSep. 2024Sep. 2023% Var. Sales1632.671494.14 9 OPM %26.8925.49 - PBDT496.94433.26 15 PBT479.43415.42 15 NP358.61312.94 15 Powered by Capital Market - Live

4 weeks agoCapital Market - Live
Corporate
Abbott India to announce Quarterly Result

Abbott India will hold a meeting of the Board of Directors of the Company on 7 November 2024Powered by Capital Market - Live

1 month agoCapital Market - Live
Corporate
Abbott India director resigns

Abbott India announced the resignation of Ashok Saini as Commercial Director - GenNext, Vaccines and Neurolife of the Company, effective close of business hours of 16 October 2024. Powered by Capital Market - Live

1 month agoCapital Market - Live
Live Market Update
Sensex, Nifty hit new life highs; auto shares in demand

The key equity indices further extended gains and hit fresh record highs in mid-morning trade. The Nifty scaled above the 25,700 level. Auto shares advanced for the second trading session. At 11:30 IST, the barometer index, the S&P BSE Sensex, climbed 967.25 points or 1.17% to 84,151.28. The Nifty 50 index advanced 278.65 points or 1.10% to 25,701.35. The Sensex and Nifty clocked an all-time high of 84,240.50 and 25,691.15, respectively in mid-morning trade. Further, the Nifty Bank also hit a life high of 53,559.35. In the broader market, the S&P BSE Mid-Cap index added 0.61% and the S&P BSE Small-Cap index advanced 1.11%. The market breadth was strong. On the BSE, 2,460 shares rose and 1,275 shares fell. A total of 148 shares were unchanged. Buzzing Index : The Nifty Auto index added 1.68% to 26,342.10. The index advanced 2.08% in two trading sessions. Mahindra & Mahindra (up 4.23%), Maruti Suzuki India (up 2.47%), Eicher Motors (up 2.11%), Bosch (up 1.52%) and TVS Motor Company (up 1.35%), Hero MotoCorp (up 1.11%), Exide Industries (up 0.71%), Bajaj Auto (up 0.57%), Bharat Forge (up 0.49%) and Balkrishna Industries (up 0.28%) edged higher. On the other hand, Samvardhana Motherson International (down 1.43%), Apollo Tyres (down 0.02%) edged lower. Stocks in Spotlight : Abbott India fell 0.22%. The company said that it has signed a non-exclusive patent license agreement with Takeda Pharmaceuticals Company to commercialize Vonoprazan, a novel molecule in the gastrointestinal therapy area, under the brand name Vonefi. Shalby rallied 3.39% after the company announced that it has received a license to operate a Bone Bank at Krishna Shalby Hospital. Global Markets: Asian stocks traded higher on Friday after Wall Street soared overnight following the Federal Reserve's outsized rate cut. Bank of Japan keeps key interest rate steady as it treads cautiously on normalizing policy. The Bank of Japan kept its benchmark interest rate steady at 'around 0.25%', the highest rate since 2008 at the conclusion of a two-day meeting Friday. Japan's economy has recovered moderately, the central bank said in its official statement, while acknowledging 'some weakness has been seen in part.' BOJ said the country's core inflation rate, which strips out fresh food prices will rise through fiscal year 2025. Japan's Core CPI, excluding volatile fresh food prices, increased by 2.8% year-on-year in August, reaching a 10-month high. This figure was in line with expectations and up from the 2.7% recorded in the previous month. A core reading that excludes both fresh food and energy prices, closely watched by the BOJ as a gauge of underlying inflation, rose to 2% in August from 1.9% in the prior month. Headline CPI inflation reached a 10-month high of 3% in August, up from 2.8% in the previous month. In China, the central bank maintained its benchmark lending rates, disappointing hopes for immediate policy support to bolster its struggling economy. China also kept its key lending rates steady, with the one-year loan prime rate at 3.35% and the five-year LPR at 3.85%. US stocks surged to new all-time highs on Thursday, as markets welcomed the Federal Reserve's aggressive interest rate cut to protect the labor market. The S&P 500 gained 1.7%, reaching 5,713.64, while the tech-heavy Nasdaq Composite Index jumped 2.5% to 18,013.98. The Fed on Wednesday reduced its key lending rate by 0.50%, opting for a larger cut after considering a quarter-point move. Powered by Capital Market - Live

2 months agoCapital Market - Live
Spotlight
Abbott India joins hand with Takeda Pharma to launch Vonoprazan tablets in India

Vonoprazan (PCAB or potassium competitive acid blocker) addresses severe acid related disorders like reflux esophagitis through a once daily dose. Current treatments for reflux esophagitis, a condition under the gastroesophageal reflux disease (GERD) umbrella, have several limitations including the need for multiple dosing for effectiveness, especially when the condition is severe. Vonoprazan, a first-of-its kind therapy, will help make it easier for patients to comply with their treatment and manage their condition better. This license will enable the company, a leader in the gut health space, to enhance access to this novel therapy to more patients across India. Abbott India has a portfolio of science-based offerings in diagnostics, medical devices, nutritionals and branded generic pharmaceuticals. The company's net profit jumped 41.1% to Rs 290.24 crore in Q1 FY24 as compared with Rs 205.64 crore in Q1 FY23. Revenue from operations was at Rs 1,479 crore in Q1 FY24, up 13.4% from Rs 1,304.12 crore reported in the same quarter previous year. Shares of Abbott India shed 0.51% to Rs 27,820.80 on the BSE.Powered by Capital Market - Live

2 months agoCapital Market - Live
Earnings
Abbott India standalone net profit rises 13.01% in the June 2024 quarter

Net profit of Abbott India rose 13.01% to Rs 328.01 crore in the quarter ended June 2024 as against Rs 290.24 crore during the previous quarter ended June 2023. Sales rose 5.32% to Rs 1557.61 crore in the quarter ended June 2024 as against Rs 1479.00 crore during the previous quarter ended June 2023. ParticularsQuarter EndedJun. 2024Jun. 2023% Var. Sales1557.611479.00 5 OPM %25.1024.00 - PBDT455.59407.66 12 PBT437.22390.49 12 NP328.01290.24 13 Powered by Capital Market - Live

3 months agoCapital Market - Live
Corporate
Abbott India to declare Quarterly Result

Abbott India will hold a meeting of the Board of Directors of the Company on 7 August 2024.Powered by Capital Market - Live

4 months agoCapital Market - Live

Dexcom plunges as revenue forecast cut spooks investors

4 months agoEconomic Times